{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:20:28Z","timestamp":1773926428845,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125699","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:59:26Z","timestamp":1765817966000},"page":"125699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study"],"prefix":"10.1016","volume":"480","author":[{"given":"Lior","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Avizov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Karni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2025.125699_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2025.125699_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2014a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.125699_bb0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2025.125699_bb0020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"10127","key":"10.1016\/j.jns.2025.125699_bb0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jns.2025.125699_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1177\/13524585221076717","article-title":"Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in SPMS: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial","volume":"28","author":"Arnold","year":"2022","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.jns.2025.125699_bb0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","article-title":"The two sides of siponimod: evidence for brain and immune mechanisms in MS","volume":"36","author":"Cohan","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jns.2025.125699_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010024","article-title":"Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action","volume":"8","author":"Behrangi","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jns.2025.125699_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1134\/S0006297917030099","article-title":"Neurotrophic factors (BDNF and GDNF) and the serotonergic system of the brain","volume":"82","author":"Popova","year":"2017","journal-title":"Biochemistry (Mosc)"},{"issue":"5","key":"10.1016\/j.jns.2025.125699_bb0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","article-title":"Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","volume":"11","author":"Devonshire","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125699_bb0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jneuroim.2008.01.010","article-title":"Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection","volume":"195","author":"Azoulay","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125699_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain-derived neurotrophic factor in serum of relapsing\u2013remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.jns.2025.125699_bb0065","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40263-019-00675-7","article-title":"Fingolimod increases brain-derived neurotrophic factor level secretion from circulating T cells of patients with multiple sclerosis","volume":"33","author":"Golan","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jns.2025.125699_bb0070","first-page":"117","article-title":"Diagnostic criteria for multiple sclerosis: 2017 revisions to the McDonald criteria","volume":"83","author":"Polman","year":"2018","journal-title":"Ann. Neurol."},{"issue":"Pt 8","key":"10.1016\/j.jns.2025.125699_bb0075","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/brain\/awq179","article-title":"Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis","volume":"133","author":"Linker","year":"2010","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.jns.2025.125699_bb0080","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.3390\/ijms24098447","article-title":"The role of BDNF in multiple sclerosis neuroinflammation","volume":"24","author":"Nociti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2025.125699_bb0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis","volume":"13","author":"Gentile","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.jns.2025.125699_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052454","article-title":"Siponimod attenuates neuronal cell death triggered by neuroinflammation via NF-\u03baB and mitochondrial pathways","volume":"25","author":"Gurrea-Rubio","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2025.125699_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68715-x","article-title":"Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models","volume":"14","author":"Hendek","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2025.125699_bb0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fphar.2020.00077","article-title":"Sphingosine-1-phosphate receptors modulators decrease signs of neuroinflammation and prevent Parkinson\u2019s disease symptoms in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model","volume":"11","author":"P\u00e9pin","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2025.125699_bb0105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1073\/pnas.96.1.254","article-title":"Neuroprotection with noninvasive neurotrophin delivery to the brain","volume":"96","author":"Wu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125699_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2009.08.057","article-title":"Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"287","author":"De Santi","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"Pt 1","key":"10.1016\/j.jns.2025.125699_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/brain\/awf015","article-title":"BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?","volume":"125","author":"Stadelmann","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.125699_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtherbio.2025.104293","article-title":"Brain-derived neurotrophic factor in peripheral blood mononuclear cells from healthy adults following acute aerobic exercise and a 6-hour recovery in temperate and hot environments","volume":"133","author":"Goulet","year":"2025","journal-title":"J. Therm. Biol."},{"key":"10.1016\/j.jns.2025.125699_bb0125","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3389\/fphys.2018.01337","article-title":"Daily intermittent normobaric hypoxia over 2 weeks reduces BDNF plasma levels in young adults - a randomized controlled feasibility study","volume":"9","author":"Becke","year":"2018","journal-title":"Front. Physiol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:46:03Z","timestamp":1773913563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"alternative-id":["S0022510X25023196"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125699","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125699"}}